{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:37:23Z","timestamp":1793122643997,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Curcumin is an ingredient of the root <jats:italic>Curcuma longa<\/jats:italic>, which is responsible for the characteristic yellow color of curcuma. Curcumin is said to have the potential ability to fight malignant diseases and to have an anti-inflammatory effect. In addition, it is used as a dietary supplement. However, one problem with the use of curcumin is its extremely low bioavailability. The aim of this study is to systematically review and critically analyze clinical studies related to the pharmacokinetics (or bioavailability) and to the use of curcumin in the treatment of malignant diseases. The platforms <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">clinicaltrials.gov<\/jats:ext-link> and PubMed served as the database for the literature research. A total of 293 available studies on curcumin were filtered according to their focus (bioavailability, therapy of malignant diseases) and other criteria (study results, main substance, topic reference, existing disease\/other research purpose, reference to malignant diseases). The studies were further analyzed regarding their outcome measures, their design (number of participants, randomization, placebo group, masking, ethical standards, sponsor, primary outcome measures, secondary outcome measures, study bias) and their findings. The analysis failed to convincingly demonstrate that curcumin has a significant, positive effect on the therapy of malignant diseases. Regarding the increase in bioavailability, positive results have been obtained, which are in proximity to the pharmaceutical industry. Independent studies could not achieve increased bioavailability of curcumin. The available reviews in the literature also do not provide convincing evidence for the efficacy of curcumin. Thus, at the time being, the use of curcumin in malignant diseases is not justified scientifically.<\/jats:p>","DOI":"10.1007\/s00210-023-02825-7","type":"journal-article","created":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T10:02:13Z","timestamp":1700042533000},"page":"3477-3491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis"],"prefix":"10.1007","volume":"397","author":[{"given":"Marten A.","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,15]]},"reference":[{"key":"2825_CR1","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/nu14245347","volume":"14","author":"EC Aguilera","year":"2022","unstructured":"Aguilera EC, Vachon A, Plourde M (2022) Comparative pharmacokinetic of curcuminoids formulations with an omega-3 fatty acids monoglyceride carrier: a randomized cross-over triple-blind study. Nutrients 14:5347. https:\/\/doi.org\/10.3390\/nu14245347","journal-title":"Nutrients"},{"key":"2825_CR2","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1021\/mp700113r","volume":"4","author":"P Anand","year":"2007","unstructured":"Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007) Bioavailability of curcumin: problems and promises. Mol Pharmaceutics 4:807\u2013818. https:\/\/doi.org\/10.1021\/mp700113r","journal-title":"Mol Pharmaceutics"},{"key":"2825_CR3","doi-asserted-by":"publisher","first-page":"684","DOI":"10.5414\/CP204058","volume":"59","author":"H Chung","year":"2021","unstructured":"Chung H, Yoon SH, Cho J-Y et al (2021) Comparative pharmacokinetics of Theracurmin, a highly bioavailable curcumin, in healthy adult subjects. CP 59:684\u2013690. https:\/\/doi.org\/10.5414\/CP204058","journal-title":"CP"},{"key":"2825_CR4","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","volume":"14","author":"N Dhillon","year":"2008","unstructured":"Dhillon N, Aggarwal BB, Newman RA et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14:4491\u20134499. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0024","journal-title":"Clin Cancer Res"},{"key":"2825_CR5","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1093\/jn\/nxab087","volume":"151","author":"P Fan\u00e7a-Berthon","year":"2021","unstructured":"Fan\u00e7a-Berthon P, Tenon M, Bouter-Banon SL et al (2021) Pharmacokinetics of a single dose of turmeric curcuminoids depends on formulation: results of a human crossover study. J Nutrition 151:1802\u20131816. https:\/\/doi.org\/10.1093\/jn\/nxab087","journal-title":"J Nutrition"},{"key":"2825_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/nutrit\/nuaa114","volume":"79","author":"JJA Ferguson","year":"2021","unstructured":"Ferguson JJA, Abbott KA, Garg ML (2021) Anti-inflammatory effects of oral supplementation with curcumin: a systematic review and meta-analysis of randomized controlled trials. Nutrition Rev 79:1043\u20131066. https:\/\/doi.org\/10.1093\/nutrit\/nuaa114","journal-title":"Nutrition Rev"},{"key":"2825_CR7","doi-asserted-by":"publisher","first-page":"5683","DOI":"10.1002\/jcp.27411","volume":"234","author":"N Hashemi Goradel","year":"2019","unstructured":"Hashemi Goradel N, Najafi M, Salehi E et al (2019) Cyclooxygenase-2 in cancer: a review. J Cell Physio 234:5683\u20135699. https:\/\/doi.org\/10.1002\/jcp.27411","journal-title":"J Cell Physio"},{"key":"2825_CR8","doi-asserted-by":"publisher","first-page":"2000977","DOI":"10.1002\/mnfr.202000977","volume":"65","author":"L Howells","year":"2021","unstructured":"Howells L, Malhotra Mukhtyar R, Theofanous D et al (2021) A systematic review assessing clinical utility of curcumin with a focus on cancer prevention. Molecular Nutrition Food Res 65:2000977. https:\/\/doi.org\/10.1002\/mnfr.202000977","journal-title":"Molecular Nutrition Food Res"},{"key":"2825_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/jcrt.JCRT_1017_20","volume":"18","author":"AK Karabo\u011fa Arslan","year":"2022","unstructured":"Karabo\u011fa Arslan AK, Uzunhisarc\u0131kl\u0131 E, Yerer MB, Bishayee A (2022) The golden spice curcumin in cancer: a perspective on finalized clinical trials during the last 10 years. J Cancer Res Therapeutics 18:19\u201326. https:\/\/doi.org\/10.4103\/jcrt.JCRT_1017_20","journal-title":"J Cancer Res Therapeutics"},{"key":"2825_CR10","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1186\/s12885-020-07256-8","volume":"20","author":"K Mansouri","year":"2020","unstructured":"Mansouri K, Rasoulpoor S, Daneshkhah A et al (2020) Clinical effects of curcumin in enhancing cancer therapy: a systematic review. BMC Cancer 20:791. https:\/\/doi.org\/10.1186\/s12885-020-07256-8","journal-title":"BMC Cancer"},{"key":"2825_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/1061186X.2016.1157883","volume":"24","author":"W Liu","year":"2016","unstructured":"Liu W, Zhai Y, Heng X et al (2016) Oral bioavailability of curcumin: problems and advancements. J Drug Targeting 24:694\u2013702. https:\/\/doi.org\/10.3109\/1061186X.2016.1157883","journal-title":"J Drug Targeting"},{"key":"2825_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2020.153218","volume":"70","author":"T Saghatelyan","year":"2020","unstructured":"Saghatelyan T, Tananyan A, Janoyan N et al (2020) Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: a comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomed 70:153218. https:\/\/doi.org\/10.1016\/j.phymed.2020.153218","journal-title":"Phytomed"},{"key":"2825_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/mnfr.201300724","volume":"58","author":"C Schiborr","year":"2014","unstructured":"Schiborr C, Kocher A, Behnam D et al (2014) The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Mol Nutr Food Res 58:516\u2013527. https:\/\/doi.org\/10.1002\/mnfr.201300724","journal-title":"Mol Nutr Food Res"},{"key":"2825_CR14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.5414\/CP202076","volume":"53","author":"A Storka","year":"2015","unstructured":"Storka A, Vcelar B, Klickovic U et al (2015) Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. CP 53:54\u201365. https:\/\/doi.org\/10.5414\/CP202076","journal-title":"CP"},{"key":"2825_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5425619","volume":"2022","author":"T Thambamroong","year":"2022","unstructured":"Thambamroong T, Seetalarom K, Saichaemchan S et al (2022) Efficacy of curcumin on treating cancer anorexia-cachexia syndrome in locally or advanced head and neck cancer: a double-blind, placebo-controlled randomised phase IIa trial (CurChexia). J Nutri Meta 2022:1\u201311. https:\/\/doi.org\/10.1155\/2022\/5425619","journal-title":"J Nutri Meta"},{"key":"2825_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fnut.2018.00138","volume":"5","author":"S Tuyaerts","year":"2019","unstructured":"Tuyaerts S, Rombauts K, Everaert T et al (2019) A Phase 2 study to assess the immunomodulatory capacity of a lecithin-based delivery system of curcumin in endometrial cancer. Front Nutr 5:138. https:\/\/doi.org\/10.3389\/fnut.2018.00138","journal-title":"Front Nutr"},{"key":"2825_CR17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/jid.2010.86","volume":"130","author":"C Zhang","year":"2010","unstructured":"Zhang C, Li B, Zhang X et al (2010) Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients\u2019 PBMCs: potential role for STAT-3 and NF-\u03baB signaling. J Invest Dermatol 130:2110\u20132119. https:\/\/doi.org\/10.1038\/jid.2010.86","journal-title":"J Invest Dermatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02825-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02825-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T10:23:55Z","timestamp":1714991035000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02825-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,15]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["2825"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02825-7","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,15]]},"assertion":[{"value":"28 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School () and officially registered as doctoral thesis project for Marten A. Khosravi. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}